NextCure (NASDAQ:NXTC) Shares Break Below 50-Day Moving Average After Earnings Miss

NextCure, Inc. (NASDAQ:NXTC)’s share price passed below its 50 day moving average during trading on Tuesday following a dissappointing earnings announcement. The stock has a 50 day moving average of $6.05 and traded as low as $5.60. NextCure shares last traded at $5.98, with a volume of 81,525 shares trading hands.

The company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.39).

Analyst Ratings Changes

NXTC has been the subject of a number of analyst reports. Wall Street Zen raised shares of NextCure from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings cut NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 26th. Finally, HC Wainwright restated a “buy” rating on shares of NextCure in a research report on Thursday, August 13th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, NextCure has a consensus rating of “Hold” and a consensus price target of $20.00.

Insiders Place Their Bets

In other news, major shareholder Adar1 Capital Management, Llc bought 5,626 shares of NextCure stock in a transaction dated Friday, October 23rd. The shares were acquired at an average price of $4.83 per share, with a total value of $27,173.58. Following the completion of the purchase, the insider owned 728,045 shares in the company, valued at $3,516,457.35. The trade was a 0.78% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have acquired a total of 15,537 shares of company stock worth $77,603 in the last quarter. Insiders own 11.90% of the company’s stock.

Hedge Funds Weigh In On NextCure

A hedge fund recently raised its stake in NextCure stock. Renaissance Technologies LLC raised its position in NextCure, Inc. (NASDAQ:NXTC) by 80.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,534 shares of the company’s stock after purchasing an additional 26,900 shares during the quarter. Renaissance Technologies LLC owned 1.68% of NextCure worth $647,000 as of its most recent SEC filing. 42.65% of the stock is currently owned by institutional investors.

NextCure Trading Down 4.6%

The company has a market capitalization of $27.39 million, a PE ratio of -0.69 and a beta of 1.22. The stock’s 50-day moving average is $6.05 and its two-hundred day moving average is $7.63.

About NextCure

NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells. NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.